All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program in progress.

[R] REMOTE PRESENTATION

Thursday, november 16

Education Session: Endometrial Cancer Basics
Welcome and Opening Keynote

Friday, november 17

Plenary Session 1: Prevention and Screening
Plenary Session 2: Disparities
Panel Discussion: Disparities
Plenary Session 3: Metabolic Liabilities
Plenary Session 4: Targeted Therapies

Saturday, november 18

Plenary Session 5: Immune Landscape
Plenary Session 6: Molecular Mechanisms

Thursday, november 16

registration
4-8 P.M.

wELCOME and Education Session
5:30- 5:35 pm

Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, North Carolina
Deborah F. DeLair, Northwell Health, Greenvale, New York
Douglas A. Levine, Merck Research Laboratories, Rahway, New Jersey

Education Session: Endometrial Cancer Basics
5:35 pm-6:35 pm

Introduction
Douglas A. Levine, Merck Research Laboratories, Rahway, New Jersey

Pathology of endometrial cancer:  the evolution from basic histology to the molecular era
Deborah F. DeLair, Northwell Health, Greenvale, New York

Management of newly diagnosed endometrial cancers and molecular classification
Douglas A. Levine, Merck Research Laboratories, Rahway, New Jersey

Navigating the complex world of adjuvant treatments and clinical trials
Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, North Carolina

break
6:35-6:45 P.M.

Welcome and Opening Keynote
6:45-7:30 P.M.

Welcome from Conference Cochairs

The future of endometrial cancer research: possibility and purpose
Kemi M. Doll, University of Washington, Seattle, Washington

Poster Session A/Opening Reception
7:30-9 P.M.

Friday, November 17

Continental Breakfast
7-8 A.M.

Plenary Session 1: Prevention and Screening
8-10 A.M.

New directions in prevention and early detection of endometrial cancers
Megan A. Clarke, National Cancer Institute, Bethesda, Maryland

Universal tumor screening for Lynch Syndrome versus germline multi-gene panel testing for all endometrial cancer patients
Heather L. Hampel, City of Hope, Duarte, California

The WID-qEC test for simple and accurate endometrial cancer detection
Martin Widschwendter, University College London, London, United Kingdom

Highlighting the combined effects of BMI and polygenic risk score on endometrial cancer risk*
Tracy A. O’Mara, QIMR Berghofer Medical Research Institute, Brisbane QLD, Australia

Proteomic profiling of endometrial carcinomas*
Dawn Cochrane, BC Cancer Cancer, Vancouver, BC, Canada

Break
10-10:20 A.M.

Plenary Session 2: disparities
10:20-12 P.M.

Racial disparities in guideline-concordant endometrial cancer treatment
Ashley S. Felix, The Ohio State University, Columbus, Ohio

Racial disparities in high grade endometrial cancers
Michele L. Coté, Indiana University, Indianapolis, Indiana

Panel discussion: disparities
11:20 A.m.-12 p.M.

Lisa Barr, Uterine Task Force, Brooklyn, New York

Neighborhood Socioeconomic Status and Endometrial Cancer Outcomes 
Charlotte R. Gamble, MedStar Washington Hospital Center, Washington, D.C. 

Lunch (On Own)
12:00-2 P.M.

Plenary Session 3: Metabolic liabilities
2:00-4:00 P.M.

Targeting Obesity for Endometrial Cancer Treatment
Victoria L. Bae-Jump, University of North Carolina, Chapel Hill, North Carolina

Understanding field carcinogenesis in obesity-related endometrial cancer
Ronald L. Chandler, Michigan State University, East Lansing, Michigan

Therapeutic modulation of the serine/threonine phosphatase PP2A for the treatment of high grade endometrial cancers
Goutham Narla, University of Michigan, Ann Arbor, Michigan

Unique metabolic changes in Lynch syndrome-associated endometrial cancer
Melinda S. Yates, University of North Carolina, Chapel Hill, North Carolina

Break
4:00-4:20 P.M.

PLENARY SESSION 4: Targeted therapies
4:20- 6:20 P.M.

Personalized adjuvant treatment in endometrial cancer
Tjalling Bosse, Leiden University Medical Center, Leiden, Netherlands

Epigenetic approaches to endometrial cancer
Rugang Zhang, MD Anderson Cancer Center, Houston, Texas

Molecular diversity of uterine serous carcinoma
Alessandro D. Santin, Yale University, New Haven, Connecticut

The combination of the glucagon like peptide-1 receptor agonist semaglutide and the progestin levonorgestrel is highly effective in preclinical studies of endometrial cancer*
Kimberly K. Leslie, University of New Mexico, Alburquerque, New Mexico

CD73 is a novel repressor of mutant β-catenin oncogenic activity in endometrial cancer*    
Rebecca M. Hirsch, University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Poster Session B/Reception
6:30 P.M.- 8 P.M.

Saturday, November 18

Continental Breakfast
7-8 A.M.

Plenary Session 5: Immune Landscape
8-10 A.M.

Spontaneous humoral responses in endometrial cancer provide a rationale for novel tumor-penetrating therapeutic antibodies
Jose R. Conejo-Garcia, Duke University, Durham, North Carolina

Strategies to overcome immunotherapy resistance in endometrial cancer
Haider S. Mahdi, University of Pittsburgh, Pittsburgh, Pennsylvania [R]

Recent therapeutic advancements in advanced endometrial cancer
Vicky Makker, Memorial Sloan Kettering Cancer Center, New York, New York

Patients with endometrial cancer and benign gynecologic conditions exhibit unique vaginal and rectal microbiomes*
Nicole R. Jimenez, University of Arizona, Phoenix, Arizona

ARID1A/B mutations retarget mSWI/SNF chromatin remodeler activity and define a spectrum of dedifferentiation in endometrial carcinoma*
Jessica D. St. Laurent, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts

Break
10-10:20 A.M.

Plenary Session 6: molecular mechanisms
10:20 A.m-12:20 P.M.

Improving response to therapies: from bench molecular mechanisms to clinical trial design
Katherine Fuh, University of California San Francisco, San Francisco, California

Novel genomic features of POLE-mutant tumors: the utility for tumor classification and identification of new driver alleles
Polina Shcherbakova, University of Nebraska Medical Center, Omaha, Nebraska

Harnessing the unique biology of CD73 for improving endometrial cancer outcomes
Jessica L. Bowser, University of North Carolina, Chapel Hill, North Carolina

Patient derived organoid as a model to study estrogen mediated endometrial cancer*
Breanna M.W. Jeffcoat, University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer*
Molly L. Parrish, University of North Carolina Chapel Hill, Chapel Hill, North Carolina

Closing Remarks
12:20 P.M.- 12:30 P.M.

Douglas A. Levine, Merck Research Laboratories, Rahway, New Jersey